STOCK TITAN

Predictive Oncology Inc - POAI STOCK NEWS

Welcome to our dedicated news page for Predictive Oncology (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Predictive Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Predictive Oncology's position in the market.

Rhea-AI Summary
Predictive Oncology (POAI) reports financial results for 2023, including a net loss of $14 million on revenue of $1.8 million. Key highlights include progress with FluGen collaboration, AI-driven study of ovarian cancer, and reduction in net loss per share. The company plans to host an investor call and webcast on April 1st.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Predictive Oncology Inc. (POAI) CEO to participate in three investor conferences, showcasing the company's AI-driven drug discovery and biologics expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
conferences
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) CEO to present at Biotech Showcase and participate in LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
conferences
Rhea-AI Summary
Predictive Oncology (Nasdaq: POAI) reported financial and operating results for the three and nine months ended September 30, 2023, including a net loss of $3.2 million on total net revenue of $0.7 million for the third quarter 2023. Highlights include successful delivery of actionable results from a campaign with Cancer Research Horizons, a molecular characterization study in collaboration with UPMC Magee-Womens Hospital, and a 22% reduction in net loss in Q3 2023 compared to Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
earnings
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) completed a multi-year study with UPMC Magee-Womens Hospital, using AI-driven machine learning models to evaluate associations between datasets and ovarian cancer patient survival. The study incorporated one of the largest sets of multi-omic data from 235 ovarian cancer patients, aiming to identify key features driving overall survival endpoints. The AI-driven models have the potential to tailor therapies to individual patients, positively affecting the overall survival of ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
AI
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) will report its financial results for the third quarter ended September 30th, 2023 before the markets open on Tuesday, November 14, 2023. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. on that day. The webcast replay will be available in the Investors section of the Predictive Oncology website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences earnings
Rhea-AI Summary
Predictive Oncology (POAI) reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter of 2023. The company initiated strategic collaborations, delivered a presentation at the Bio International Convention, and relocated its corporate headquarters to Pittsburgh, PA. Predictive Oncology's financial summary for Q2 2023 includes $14.8 million in cash and cash equivalents, $14.7 million in Stockholder’s Equity, and a loss per common share of $0.98. The company recorded revenue of $490,110 in Q2 2023, with gross profit margin increasing to 67%. However, G&A expenses, operations expenses, and sales and marketing expenses all increased compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
conferences earnings
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) announced the relocation of its corporate headquarters to its main laboratory facility in Pittsburgh, PA, a global life sciences hub. The move reinforces the company’s commitment to scientific discovery and growth potential, leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory, and Good Manufacturing Practices (GMP) facility. The new location in Pittsburgh further solidifies the company's footprint and expansion of the laboratory and center for artificial intelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
management
Predictive Oncology Inc

Nasdaq:POAI

POAI Rankings

POAI Stock Data

11.30M
3.62M
3.14%
9.09%
0.44%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Eagan

About POAI

predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries